Table 2 of Ecker, Mol Vis 2012; 18:1658-1667.

Table 2. Group 1 (subretinal fluid) demographics.



Patient

Age

Initial VA

Final VA		 Study
vitreous
sample/injections
1 85 20/63 20/40 4
2 70 20/50 20/20 7
3 66 20/100 20/100 7
4* 90 20/50 20/80 7
5* 63 20/100 20/63 6
6* 73 20/63 20/32 8

* Patient 4 and 5 had intravitreal triamcinolone, at visit 8 and 6 respectively. Patient 6 was switched to ranibizumab on visits 6–7. All other injections were bevacizumab 0.05 ml/1.25 mg.

Ecker, Mol Vis 2012; 18:1658-1667. http://www.molvis.org/molvis/v18/a171

©2012 Molecular Vision http://www.molvis.org/molvis/

ISSN 1090-0535